These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32250720)

  • 21. Renal immune-related adverse events of immune checkpoint inhibitor.
    Hu R; Chen M; Xu Y; Wang M; Zheng K; Li X
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):305-311. PubMed ID: 32573099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity Paradox in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy-Reply.
    Kichenadasse G; Hopkins AM; Sorich MJ
    JAMA Oncol; 2020 Jun; 6(6):941-942. PubMed ID: 32324194
    [No Abstract]   [Full Text] [Related]  

  • 24. Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
    Yang Z; Wei S; Liu L
    JAMA Oncol; 2020 Apr; 6(4):587. PubMed ID: 32077898
    [No Abstract]   [Full Text] [Related]  

  • 25. Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
    Huang XZ; Gao P; Wang ZN
    JAMA Oncol; 2020 Apr; 6(4):586-587. PubMed ID: 32077902
    [No Abstract]   [Full Text] [Related]  

  • 26. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.
    Kubo T; Watanabe H; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Rai K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2020 Dec; 50(12):1447-1453. PubMed ID: 32869100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis.
    Doms J; Prior JO; Peters S; Obeid M
    Ann Oncol; 2020 Sep; 31(9):1273-1275. PubMed ID: 32425357
    [No Abstract]   [Full Text] [Related]  

  • 28. Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis.
    Özdemir BC; Latifyan S; Perreau M; Fenwick C; Alberio L; Waeber G; Spertini F; de Leval L; Michielin O; Obeid M
    Ann Oncol; 2020 Dec; 31(12):1775-1778. PubMed ID: 32858151
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator? Author's reply.
    Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1168. PubMed ID: 28326587
    [No Abstract]   [Full Text] [Related]  

  • 30. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
    de Almeida DVP; Fong L; Rettig MB; Autio KA
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-18. PubMed ID: 32343604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A measuring method for occupancy of immune checkpoint inhibitors in the cell surface.
    Yanagihara T; Tanaka K; Matsumoto K
    Biochem Biophys Res Commun; 2020 Jun; 527(1):213-217. PubMed ID: 32446369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.
    Sanders S; Debinski W
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.
    Fan S; Ren H; Zhao L; Yin J; Feng G; Wang J; Guan H
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):291-298. PubMed ID: 32893999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.
    Cramer P; Bresalier RS
    Curr Gastroenterol Rep; 2017 Jan; 19(1):3. PubMed ID: 28124291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter to Yokoyama et al. (Yokoyama Y. Cytokine. 2017 Dec 29; 103: 25-28).
    Rodríguez-Lago I; Cabriada JL
    Cytokine; 2018 Apr; 104():29. PubMed ID: 29414323
    [No Abstract]   [Full Text] [Related]  

  • 37. Immune checkpoint inhibitor-induced bullous pemphigoid: Towards a new class of drug-drug interaction?
    Pujalte-Martin M; Rocher F; Cardot-Leccia N; Giacchero D; Borchiellini D
    Eur J Cancer; 2020 Oct; 138():122-124. PubMed ID: 32877796
    [No Abstract]   [Full Text] [Related]  

  • 38. Unusual flaccid blistering with mucosal involvement upon immune checkpoint inhibition.
    Niebel D; Brägelmann C; Wenzel J; Bieber T
    J Dtsch Dermatol Ges; 2020 Feb; 18(2):149-152. PubMed ID: 31596533
    [No Abstract]   [Full Text] [Related]  

  • 39. Response to Dai et al. and Gracie et al.
    Kochar B; Barnes EL; Long MD; Cushing KC; Galanko J; Martin CF; Raffals LE; Sandler RS
    Am J Gastroenterol; 2018 May; 113(5):774-775. PubMed ID: 29681625
    [No Abstract]   [Full Text] [Related]  

  • 40. Value of first-line surgical treatment for classic Kaposi sarcoma and potential use of checkpoint inhibitors.
    Reschke R; Grunewald S; Schüürmann M; Simon JC; Ziemer M
    J Dtsch Dermatol Ges; 2020 Mar; 18(3):256-262. PubMed ID: 32065706
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.